ImmunityBio announced on April 21, 2026 that ANKTIVA® (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia, with initial patients identified for treatment across both approved bladder and lung cancer indications. The SFDA is the first regulatory authority globally to grant conditional approval for Anktiva for the treatment of metastatic non-small cell lung cancer (NSCLC), where it is administered via subcutaneous injection for patients whose disease has progressed after standard of care. The drug was brought to market within two months of ImmunityBio's MENA partnership announcement, reflecting the Kingdom's increasing ability to achieve rapid commercial launches following regulatory approval.
Raising the standard for excellence in care.
Raising the standard for excellence in care.